Oric Pharmaceuticals (NASDAQ:ORIC) is fully committed to the development and innovation of therapies aimed at overcoming resistance in cancer treatment. Based in the heart of the biotechnology sector, Oric Pharmaceuticals focuses on a robust pipeline of targeted anti-cancer drugs. These cutting-edge projects are designed to address the complex challenges faced by patients who have developed resistance to current cancer therapies. The objectives of Oric are deeply rooted in the belief that through scientific rigor and a dedicated approach to research, it is possible to unlock new pathways in oncology, providing hope and improved outcomes for patients facing this tough battle.